Tudor Investment Corp
LFCR icon

Tudor Investment Corp’s Lifecore Biomedical LFCR Stock Holding History

Tudor Investment Corp’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-52,500
Closed -$641K – 1318
2013
Q3 		$641K Buy
+52,500
New +$733K 0.03% 235

Other funds holding LFCR

GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
KG
Killen Group Berwyn, Pennsylvania $866M AUM 0.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tudor Investment Corp's LFCR Position: Q4 2013 in Review

Tudor Investment Corp sold out of Lifecore Biomedical (LFCR) in Q4 2013, closing a stake of 52,500 shares — an estimated $641K sold.

Tudor Investment Corp first reported a position in LFCR in Q3 2013 and held it in 1 quarter. The position peaked at $641K in Q3 2013. 111 funds tracked by Wall St. Rank hold LFCR as of Q4 2013.

  • Tudor Investment Corp reported no remaining Lifecore Biomedical position as of Q4 2013 after selling out during the quarter.
  • Tudor Investment Corp sold 52,500 Lifecore Biomedical shares in Q4 2013, an estimated $641K.
  • Tudor Investment Corp first reported a position in Lifecore Biomedical in Q3 2013 and held it in 1 quarter.
  • Tudor Investment Corp's Lifecore Biomedical position peaked at $641K in Q3 2013.
  • 111 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2013.

Based on Tudor Investment Corp's 13F filing for Q4 2013, filed 14 Feb 2014.